HIV-1 p24 (Detection Ab) (clone E12), anti-human

Background:
-Acquired immune deficiency syndrome (HIV/AIDS) has been a major global health concern for over 38 years. No safe and effective preventive or therapeutic vaccine has been developed although many products have been investigated. Computational methods have facilitated vaccine developments in recent decades. Among HIV-1 proteins, p24 and Nef are two suitable targets to provoke the cellular immune response. The predicted fusion protein, p24-AAY-Nef in a truncated form with a high rate of T cell epitopes and high conservancy rate among different clades, provides a helpful model for developing a therapeutic vaccine candidate against HIV-1. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in intracellular plasma membrane-connected structures termed virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. The transmembrane domain of Vpu and two motifs of the Vpu cytoplasmic domain are required for these functions. These motifs were notably involved in the control of the volume of VCCs by Vpu but were dispensable for the prevention of the specific accumulation of BST2 in these structures.-

Immunogen:
-Recombinant human HIV-1 p24 Protein (Expression system with E.Coli).---

Matched antibody pair: -Capture Ab: HIV-1 p24 mAb (clone # B8), Detection Ab: HIV-1 p24 mAb (clone # E12)-

Recommended Application:
-ELISA-

Product Form: -Liquid-

Purification & Buffer: -Protein A or G purified and supplied in 0.9% NaCl without preservative.-

Purity: ->95% by HPLC & SDS-PAGE-

Storage Instruction:
-Aliquot and store at -20℃ for long term (at least for one year). Avoid repeated freeze and thaw cycles.